CN101255180A - Diphenyl ethylene glycosides derivatives - Google Patents
Diphenyl ethylene glycosides derivatives Download PDFInfo
- Publication number
- CN101255180A CN101255180A CNA2007100204437A CN200710020443A CN101255180A CN 101255180 A CN101255180 A CN 101255180A CN A2007100204437 A CNA2007100204437 A CN A2007100204437A CN 200710020443 A CN200710020443 A CN 200710020443A CN 101255180 A CN101255180 A CN 101255180A
- Authority
- CN
- China
- Prior art keywords
- stilbene glucoside
- solvent
- ethyl acetate
- ethanol
- stilbene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Diphenyl ethylene glycosides Chemical class 0.000 title claims abstract description 96
- 229930182470 glycoside Natural products 0.000 title description 4
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims abstract description 101
- 235000021286 stilbenes Nutrition 0.000 claims abstract description 93
- 229930182478 glucoside Natural products 0.000 claims abstract description 92
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000013078 crystal Substances 0.000 claims abstract description 16
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 14
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 14
- 239000003960 organic solvent Substances 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 238000004440 column chromatography Methods 0.000 claims abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 79
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 239000002904 solvent Substances 0.000 claims description 24
- 238000000605 extraction Methods 0.000 claims description 23
- 239000012043 crude product Substances 0.000 claims description 22
- 238000002425 crystallisation Methods 0.000 claims description 14
- 239000011347 resin Substances 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 14
- 230000008025 crystallization Effects 0.000 claims description 13
- 239000000287 crude extract Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000012046 mixed solvent Substances 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 7
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000001953 recrystallisation Methods 0.000 claims description 6
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000012044 organic layer Substances 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 8
- 238000009776 industrial production Methods 0.000 abstract description 3
- JAYVHSBYKLLDJC-NUABRCLCSA-N (2s,3r,4s,5s,6r)-2-[2,4-dihydroxy-6-[2-(4-hydroxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(O)C=C(O)C=C1C=CC1=CC=C(O)C=C1 JAYVHSBYKLLDJC-NUABRCLCSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000013558 reference substance Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- JAYVHSBYKLLDJC-DSNJPTTOSA-N (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(O)C=C(O)C=C1\C=C\C1=CC=C(O)C=C1 JAYVHSBYKLLDJC-DSNJPTTOSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000274 adsorptive effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 229910017541 Cu-K Inorganic materials 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
Images
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a new type 2, 3, 5, 4'- tetra-hydroxyl diphenyl ethylene-2-O-beta-D-glucoside crystal, a method for making same, and pharmaceutical compositions containing the crystal. The content of the crystal is 90-99. 9tested by high performance liquid chromatography, and the stilbene glucoside crystal of high-purity is obtained by abstracting fleece-flower root, extracting with an organic solvent, separating by column chromatography and crystallizing in appropriate dissolvent. The preparing process provides high yield, low cost, and is suitable for industrial production.
Description
Technical field
The invention belongs to medical technical field, relate to effective monomer 2,3,5,4 in the Tuber Fleeceflower Root '-separation purifying technique of tetrahydroxystilbene-2-O-β-D-glucoside; Also relate to 2,3,5,4 '-crystal of tetrahydroxystilbene-2-O-β-D-glucoside and preparation method thereof, and be the pharmaceutical composition of main component with it.
Background technology
Tuber Fleeceflower Root is the piece root of polygonum multiflorum thunb (pllygonum multiflorum Thunb.), is conventional Chinese medicine, and medicinal history is long, The experimental results both domestic and external shows: Tuber Fleeceflower Root has immunomodulatory, protect the liver many-sided pharmacologically active such as anti-oxidant, antitumor, reducing blood-fat.Along with going deep into of research, also more and more clear to its The Chemical Constituents, studies show that in a large number, in the Tuber Fleeceflower Root what play a major role is 2,3,5,4 '-tetrahydroxystilbene-2-O-β-D-glucoside (hereinafter to be referred as stilbene glucoside).The physiologically active of stilbene glucoside mainly contains: anti-aging effects, reducing blood lipid, liver protection function, improve memory function, antitumor action etc. (referring to Shandong heavily fortified point, Hou Shuanqiu etc., Research Progress on Stilbene Glucoside, the Anhui chemical industry, 2006 (3), 10～13).The application of stilbene glucoside in the treatment dementia disclosed among the Chinese patent ZL01134284.6.The application of stilbene glucoside in the treatment ischemic cerebrovascular disclosed among the Chinese patent application CN01134283.8.
Along with the medicinal efficacy of stilbene glucoside constantly is found, industrial hope obtains a large amount of suitable medicinal stilbene glucoside raw materials, describedly is fit to medicinal stilbene glucoside raw material and should possesses higher purity at least and prepare the desired physical properties of preparation.But because the restriction of state of the art, the separation and purification of high purity stilbene glucoside still is in the level of laboratory minute quantity preparation always, do not see the report that the high purity of suitable suitability for industrialized production scale stilbene glucoside preparation technology is arranged, therefore, carrying out the separation purifying technique that is fit to medicinal stilbene glucoside studies significant.
At present, the main methods such as high performance liquid chromatography, crystallization process, resin column that adopt prepare highly purified stilbene glucoside in the prior art.
Though high performance liquid chromatography can access the stilbene glucoside of based on very high purity, its purification efficiency is difficult to improve, and the purifying cost is also higher relatively, thereby this method is mainly used in prepared in laboratory, is difficult to be applied to suitability for industrialized production.
People such as class's assist disclose a kind of method (referring to class's assist, Liu Qili, Jin You etc., the stability study of stilbene glucoside, herbal medicine, 2004,35 (11), 1235～1237) of crystal refining stilbene glucoside.This method is utilized the Tuber Fleeceflower Root medicinal extract of ethanol refluxing process gained, with behind an amount of distilled water diluting with equivalent extracted with diethyl ether 3 times, isolate water layer; The vinyl acetic monomer layer is collected in the vinyl acetic monomer thermal backflow of water layer usefulness two volumes 5～6 hours, is evaporated to 1/10 of original volume, and room temperature leaves standstill, and crystallization filters, and gets crude product.Crude product dissolves in an amount of hot water or hot vinyl acetic monomer, filters while hot, puts the cold analysis crystalline substance, periodic crystallisation like this, grey imperfect crystal formation powder, mp.162～163 ℃, by analysis, stilbene glucoside purity is 99.94%.Though this method can access the very high toluylene glycoside product of purity, need the repeated multiple times crystallization, technology is loaded down with trivial details, and the organic solvent consumption is big, and resource utilization is low, and will use inflammable and explosive reagent such as ether, is not suitable for suitability for industrialized production.
Other documents disclose the method that adopts macroporous adsorbent resin separation and purification stilbene glucoside (referring to Zhu Haisheng etc., the research of macroporous adsorbent resin separation and purification Tuber Fleeceflower Root effective constituent stilbene glucoside, PLA's Acta Pharmaceutica Sinica, 2006,22 (4), 269～273 and Lv Lishuan etc., the technical study of stilbene glucoside in the macroporous resin purification Tuber Fleeceflower Root, Food science, 2005,6 (26), 178～181).These documents also all are based on the fundamental research that laboratory study is carried out, and used amount of resin generally also has only several grams, also can't compare with industrialized producing technology, and the stilbene glucoside purity that makes also reach monomeric specification of quality far away.
In addition, Chinese patent ZL 98120290.X discloses a kind of method for preparing stilbene glucoside, the chromatography column that this method will be used for separation and purification carries out the destructiveness cutting, the separation of taking a sample again, process is loaded down with trivial details, cost is high, also is the method for typical prepared in laboratory micro-example, can't reach industrial production requirement.
The invention provides a kind of extraction and separation method of stilbene glucoside, this method is easy and simple to handle, with low cost, stable yield, can satisfy the demand of suitability for industrialized production scale fully, the stilbene glucoside purity that makes can obtain highly purified toluylene glycosidal crystalline when guaranteeing that low-cost and high receipts are considered, reached industrial production requirement.The present invention also provides a kind of stilbene glucoside of new physics form in addition, and the pharmaceutical composition that contains this form, and new physical aspect has the physical properties of preparation preparation preferably.
Summary of the invention
The object of the present invention is to provide the method for a kind of extraction separation structure suc as formula 1 compound, described extraction and separation method is as follows:
Formula I
A) extract: get the Tuber Fleeceflower Root medicinal material, drink in cataclasm, the mixed solvent that adds one or more solvent compositions in a certain amount of water, methyl alcohol, the ethanol, regulate pH to 7.0～8.0 of extracting solution, heating is extracted 1～4 time, each 1～3 hour, Heating temperature is 40 a ℃～reflux temperature, united extraction liquid is put coldly, filters.Wherein extract the solvent preferably water; What regulate extracting liquid pH value can be acid, alkali or salt, and preferred sodium hydroxide, S-WAT, sodium bisulfite, yellow soda ash most preferably are S-WAT; The pH value of extracting solution is preferably 7.5; Preferred extraction 3 times, each 1.5 hours are extracted in heating.
B) separate: said extracted liquid is crossed macroporous resin column, after adding the abundant wash-out of water and removing inorganic salt and other impurity in the extracting solution, use certain density organic solvent wash-out instead, collect the elutriant that contains stilbene glucoside.The model of macroporous resin can be HPD-400, HPD-100, AB-8, D1300, and preferred macroporous resin model is HPD-400; Eluting solvent can be preferably ethanol for ethanol, methyl alcohol or acetone, and more preferably concentration is 70% ethanol.
C) extraction: 1/10～1/30 (V/V) that elutriant is evaporated to former effluent volume under 60～80 ℃, can add an amount of water as the concentrated solution volume is less, add the sherwood oil, ether, chloroform, ethyl acetate of 1～2 times of concentrated solution volume or n-butanol extraction 2～4 times, the collected organic layer extraction liquid, the organic layer extraction liquid is evaporated to dried, obtains the solid crude extract; Preferably elutriant is concentrated into 1/20 of original volume.Extract used organic solvent ethyl acetate; Preferably use 1 times the organic solvent extraction 3 times of concentrated solution volume.
D) purifying: above-mentioned crude extract is dissolved in appropriate amount of organic, crosses chromatography column, selects for use appropriate solvent to carry out wash-out, collects the elutriant that contains the stilbene glucoside composition, concentrates, and drying gets the stilbene glucoside crude product.The filler of chromatography column can be silica gel or aluminum oxide, preferred aluminum oxide; The order number is 100-200 order or 200-300 order, is preferably the 200-300 order; Dissolving crude extract solvent for use can be acetone, ethanol, ethyl acetate before the column chromatography, is preferably ethanol; Used elutriant can be the mixed solvent of one or more solvent compositions in acetone, ethyl acetate, ethanol, methyl alcohol or the chloroform in the column chromatography process, is preferably ethyl acetate.
E) crystallization: with above-mentioned stilbene glucoside crude product at acetone, water, methyl alcohol, ethanol, heating for dissolving in the mixed solvent of one or more solvent compositions in the ethyl acetate, preferred recrystallisation solvent is an acetone: water: the mixed solvent of ethyl acetate, its ratio is 1～10: 5～20: 1～10 (V: V: V), acetone most preferably: water: ethyl acetate is 2: 10: 1 (V: V: V), the consumption of recrystallisation solvent is 1～10 times (V/W) for the stilbene glucoside crude product, preferred solvent load is 5 times (V/W) of stilbene glucoside crude product, activated carbon decolorizing, filter, leave standstill crystallization, Tc is-20～10 ℃, be preferably-10～5 ℃, optimum temps is-4 ℃, filters, drying promptly obtains highly purified stilbene glucoside.
Stilbene glycoside extract of the present invention detects its purity with high performance liquid chromatography and can reach more than 90%, preferably more than 95%, most preferably more than 98%.
The assay of stilbene glucoside adopts high performance liquid chromatography (HPLC) method to carry out among the present invention.Use therein 2,3,5,4 '-tetrahydroxystilbene-2-O-β-D-glucoside reference substance is purchased in Nat'l Pharmaceutical ﹠ Biological Products Control Institute; The moving phase of using is acetonitrile: water=15: 85; Detector is JASW UV-1575; Flow velocity is 1mL/min; Chromatographic column adopting Agilent Extend C-18 (4.6mm * 250mm, 5 μ m); Column temperature is 30 ℃, and concrete testing method is as follows:
1. the foundation of typical curve
Precision takes by weighing 2,3,5,4 '-tetrahydroxystilbene-2-O-β-D-glucoside reference substance 5.15mg, with water dissolution and be settled to 100ml, be made into the reference substance storing solution, get storing solution 1ml respectively, 2ml, 4ml, 6ml, 8ml, each self-watering is settled to 10ml, get the reference substance solution 20 μ l of above-mentioned each concentration respectively, injecting chromatograph obtains the peak area data shown in the table one successively, make the stilbene glucoside typical curve shown in the table two thus, be good linear relationship between visible sample size and peak area.
Linearity range: 5～50 μ g/ml
Regression equation is: Y=80909X+19722
Relation conefficient: R=0.9992
Table one stilbene glucoside standard substance concentration and peak area data
| Concentration (μ g/ml) | 5.15 | ?10.30 | ?20.60 | ?30.90 | ?41.20 |
| Peak area (mv/s) | 415797 | ?888128 | ?1706896 | ?2445922 | ?3392192 |
2. the content assaying method of stilbene glucoside sample
Accurately take by weighing stilbene glucoside reference substance (abbreviation reference substance) and each 20.00mg of homemade stilbene glucoside sample (abbreviation trial-product), use water dissolution respectively, and be settled to 100ml, and respectively get the 1ml thin up and be settled to 10ml, obtain reference substance solution and need testing solution.Draw each 20 μ l of above-mentioned two kinds of solution injecting chromatograph successively respectively, the record peak area, the utilization external standard method is calculated, and obtains the content of stilbene glucoside in the trial-product.
The high-efficient liquid phase chromatogram of stilbene glucoside of the present invention and stilbene glucoside reference substance (purchasing in Nat'l Pharmaceutical ﹠ Biological Products Control Institute) is shown in accompanying drawing 5 and accompanying drawing 6.
Novel crystal that provides stilbene glucoside and preparation method thereof is provided another object of the present invention,
A further object of the present invention is to provide and contains described stilbene glucoside crystalline pharmaceutical composition.
Not moisture substantially and other organic solvent of stilbene glucoside crystal of the present invention, its X-ray powder diffraction spectrogram (this collection of illustrative plates is with Cu-K α radiation measurement on the X`TRA-X x ray diffractometer x), be 4.772,4.471,3.678 in the d value, located diffraction peak, typically at 14.572,12.200,4.772,4.471,3.678,3.622 places diffraction peak is arranged, more typical have diffraction peak at 14.572,12.200,7.320,4.772,4.471,3.678,3.622,3.343,2.384 places.
Stilbene glucoside crystalline differential scanning calorimetric analysis of the present invention (adopting NETZSCH DSC 204 F1 instruments) heats up with 10K/ minute speed, and it absorbs the heat deflection peak value and is about 178 ℃.
Stilbene glucoside crystal of the present invention uses the infrared absorption spectrum of KBr compressing tablet mensuration at 3333cm
-1(broad peak), 1607cm
-1, 1593cm
-1, 1515cm
-1There is absorption peak at the place.
Stilbene glucoside crystalline thermogravimetic analysis (TGA) collection of illustrative plates of the present invention as shown in Figure 4.
Stilbene glucoside crystal of the present invention can be by the preparation of following method: with stilbene glucoside crude product or pure product at acetone, water, methyl alcohol, ethanol, heating for dissolving in the mixed solvent of one or more solvent compositions in the ethyl acetate, preferred recrystallisation solvent is an acetone: water: the mixed solvent of ethyl acetate, its ratio is 1～10: 5～20: 1～10 (V: V: V), acetone most preferably: water: ethyl acetate is 2: 10: 1 (V: V: V), the consumption of recrystallisation solvent is 1～10 times (V/W) for the stilbene glucoside crude product, preferred solvent load is 5 times (V/W) of stilbene glucoside crude product, activated carbon decolorizing, filter, leave standstill crystallization, Tc is-20～10 ℃, be preferably-10～5 ℃, optimum temps is-4 ℃, filters, drying promptly obtains highly purified toluylene glycosidal crystalline.
The stilbene glucoside crystal that makes according to above-mentioned steps, can also mix with suitable pharmaceutical excipient, make the composition of a definite form, comprise tablet, capsule, dripping pill, soft capsule, injection liquid or other dosage form that is suitable for using, use clinically with convenient.
The invention provides a kind of content height, definite ingredients, quality controllable, drug effect is definite, side effect is little novel toluylene glycosidal crystalline and preparation method thereof, the toluylene glycosidal crystalline is different from unformed stilbene glucoside, it is more stable, solubleness is all different with bioavailability simultaneously, wherein the easier medicament that is prepared into of toluylene glycosidal crystalline.Contain high purity stilbene glucoside crystalline pharmaceutical composition so present invention includes, this pharmaceutical composition is obvious in treatment hyperlipidemia, atherosclerosis, effect such as anti-oxidant.Preparation technology of the present invention produces checking by many batches, proves that its repeatability, stability are all good, and the total recovery height, only needs a step crystallization, not only is suitable for industrialized production but also reduced production cost.The stilbene glucoside purity height of method provided by the present invention preparation, impurity is few, has not only improved shortcomings such as the taking dose that Chinese patent medicine often has is big, composition is indeterminate, and its drug effect is remarkable clinically, have good suitability.
Description of drawings
Fig. 1 stilbene glucoside crystalline X-ray powder diffraction spectrogram.
Fig. 2 stilbene glucoside crystalline differential scanning calorimetric analysis (DSC) collection of illustrative plates.
Fig. 3 stilbene glucoside crystalline infrared absorption pattern.
Fig. 4 stilbene glucoside crystalline thermogravimetic analysis (TGA) (TGA) collection of illustrative plates.
Fig. 5 stilbene glucoside crystalline high-efficient liquid phase chromatogram.
The high-efficient liquid phase chromatogram of Fig. 6 stilbene glucoside reference substance.
Fig. 7 stilbene glucoside typical curve
Embodiment:
Following non-limiting example is for novel high purity stilbene glucoside crystalline preparation method provided by the present invention is described better, and does not mean that any limitation of the invention.
In the following example, used extraction water is a tap water; Used ethanol is pharmaceutical grade; The Tuber Fleeceflower Root medicinal material place of production is Bozhou, an Anhui Chinese Medicinal Materials Markets; Silica gel and aluminum oxide are all available from Qingdao Marine Chemical Co., Ltd..
Get exsiccant Tuber Fleeceflower Root medicinal material 100kg, be cut into the thin slice of 1-3mm, the thermal backflow extractor of packing into, the water and the S-WAT that add 10 times of amounts are an amount of, regulate extracting solution pH to 7.6, heating and refluxing extraction 3 times, each 1 hour, united extraction liquid filtered, and collects filtrate.Filtrate is crossed the HPD-400 macroporous adsorptive resins, after adding water 500L wash-out, add 80% ethanol elution, collection contains the elutriant of stilbene glucoside, amounts to 200L, is evaporated to 10L in 60 ℃, add ethyl acetate extraction 3 times, each consumption 10L, 60 ℃ of concentrating under reduced pressure acetic acid ethyl fluids get stilbene glucoside crude extract 2.5kg to doing.
Get above-mentioned crude extract, add ethanol 5.0L, heated and stirred is fully dissolved it, filter, filtrate is crossed 200-300 order neutral alumina chromatography column, uses eluent ethyl acetate instead after upper prop is finished, the thin layer monitoring, collection contains the elutriant of stilbene glucoside component, is evaporated to driedly in 50 ℃, obtains stilbene glucoside crude product 1.82kg.
Get above-mentioned crude product, add acetone: water: ethyl acetate (2: 10: 1, V/V/V) 9L, 60 ℃ are heated to dissolving, after adding proper amount of active carbon, reflux 15 minutes, filtered while hot, filtrate is put under-5 ℃ of conditions and was left standstill 15 hours, after crystallization is abundant, filter, drying obtains white toluylene glycosidal crystalline 1.28kg.Get above-mentioned sample, carry out assay with high performance liquid chromatography, the stilbene glucoside content in crude product is 90.3%, and stilbene glucoside crystalline content is 98.9%.
Embodiment 2
Get exsiccant Tuber Fleeceflower Root medicinal material 100kg, be ground into meal, the thermal backflow extractor of packing into, the water and the sodium bisulfite that add 8 times of amounts are an amount of, regulate extracting solution pH to 7.5, heating and refluxing extraction 2 times, each 2 hours, united extraction liquid filtered, and collects filtrate.Filtrate is crossed the HPD-100 macroporous adsorptive resins, after adding water 600L wash-out, add 70% ethanol elution, collect the elutriant that contains stilbene glucoside, amount to 300L, be evaporated to 15L in 70 ℃, add n-butanol extraction 2 times, each consumption 15L, 80 ℃ of concentrating under reduced pressure, concentrate propyl carbinol to doing, get stilbene glucoside crude extract 2.3kg.
Get above-mentioned crude extract, add ethyl acetate 8.0L, heated and stirred is fully dissolved it, filter, filtrate is crossed 200-300 order silica gel column chromatography, uses ethyl acetate after upper prop is finished instead: acetone (2: 1) wash-out, the thin layer monitoring, collection contains the elutriant of stilbene glucoside component, is evaporated to driedly in 60 ℃, obtains stilbene glucoside crude product 1.60kg.
Get above-mentioned crude product, add entry: ethyl acetate (20: 1, V/V) 8L, 60 ℃ are heated to dissolving, after the adding proper amount of active carbon, and reflux 5 minutes, filtered while hot, filtrate is put under-10 ℃ of conditions and was left standstill 10 hours, after crystallization is abundant, filters, dry, obtain white toluylene glycosidal crystalline 1.28kg, crystallization is a needle-like, assembles cluster.Get above-mentioned sample, carry out assay with high performance liquid chromatography, the stilbene glucoside content in crude product is 91.1%, and stilbene glucoside crystalline content is 99.6%.
Embodiment 3
Get exsiccant Tuber Fleeceflower Root medicinal material 120kg, be ground into meal, the thermal backflow extractor of packing into, the water and the yellow soda ash that add 7 times of amounts are an amount of, regulate extracting solution pH to 7.8, heating and refluxing extraction 3 times, each 1.5 hours, united extraction liquid filtered, and collects filtrate.Filtrate is crossed the AB-8 macroporous adsorptive resins, after adding water 600L wash-out, add 90% ethanol elution, collect the elutriant that contains stilbene glucoside, amount to 320L, be evaporated to 20L in 70 ℃, add ethyl acetate extraction 3 times, each consumption 20L, 80 ℃ of concentrating under reduced pressure, concentrate ethyl acetate to doing, get stilbene glucoside crude extract 2.92kg.
Get above-mentioned crude extract, add acetone 12L, heated and stirred is fully dissolved it, filter, filtrate is crossed 200-300 order neutral alumina post, uses eluent ethyl acetate instead after upper prop is finished, the thin layer monitoring, collection contains the elutriant of stilbene glucoside component, is evaporated to driedly in 50 ℃, obtains stilbene glucoside crude product 1.9kg.
Get above-mentioned crude product, add acetone: water: ethyl acetate (1: 10: 1, V/V/V) 10L, 50 ℃ are heated to dissolving, after the adding proper amount of active carbon, and reflux 10 minutes, filtered while hot, filtrate is put under-4 ℃ of conditions and was left standstill 20 hours, after crystallization is abundant, filters, dry, obtain white toluylene glycosidal crystalline 1.51kg, crystallization is a needle-like, assembles cluster.Get above-mentioned sample, carry out assay with high performance liquid chromatography, the stilbene glucoside content in crude product is 92.8%, and stilbene glucoside crystalline content is 99.9%.
Claims (12)
1. the method for the following compound of an extraction separation structural formula, described extraction and separation method comprises:
A. get the Tuber Fleeceflower Root medicinal material, drink in cataclasm, add the mixed solvent of one or more solvent compositions in entry, methyl alcohol, the ethanol, regulate pH to 7.0～8.0 of extracting solution, heating is extracted, and puts coldly, filters;
B. said extracted liquid is crossed macroporous resin column, after adding water elution, use the organic solvent wash-out instead, collect the elutriant that contains stilbene glucoside, the model of macroporous resin can be HPD-400, HPD-100, AB-8, D1300, and eluting solvent can be ethanol, methyl alcohol or acetone;
C. with the elutriant concentrating under reduced pressure, add sherwood oil, ether, chloroform, ethyl acetate or n-butanol extraction, the collected organic layer extraction liquid is evaporated to the organic layer extraction liquid dried, obtains the solid crude extract;
D. above-mentioned crude extract is dissolved in organic solvent, cross chromatography column, collection contains the elutriant of stilbene glucoside composition, concentrate, drying gets the stilbene glucoside crude product, the filler of chromatography column can be silica gel or aluminum oxide, the order number is 100-200 order or 200-300 order, and dissolving crude extract solvent for use can be acetone, ethanol, ethyl acetate before the column chromatography, and used elutriant can be the mixed solvent of one or more solvent compositions in acetone, ethyl acetate, ethanol, methyl alcohol or the chloroform in the column chromatography process;
E. with heating for dissolving in the mixed solvent of one or more solvent compositions of above-mentioned stilbene glucoside crude product in acetone, water, methyl alcohol, ethanol, ethyl acetate, the consumption of recrystallisation solvent is 1～10 times (V/W) for the stilbene glucoside crude product, activated carbon decolorizing, filter, leave standstill crystallization, Tc is-20～10 ℃, filters, drying promptly gets stilbene glucoside.
2. among the claim 1 step a, the extraction solvent is a water.
3. among the claim 1 step b, the macroporous resin model is HPD-400.
4. among the claim 1 step b, eluting solvent is an ethanol.
5. among the claim 1 step c, extracting used organic solvent is ethyl acetate.
6. in claim 1 steps d, the filler of chromatography column is an aluminum oxide.
7. in claim 1 steps d, used elutriant is an ethyl acetate in the column chromatography process.
8. among the claim 1 step e, recrystallisation solvent is an acetone: water: ethyl acetate is 1～10: 5～20: 1～10 mixed solvent, solvent load are 5 times of stilbene glucoside crude product.
9. the stilbene glucoside crystal of not moisture substantially and other organic solvent is characterized in that: its X-ray powder diffraction spectrogram is 4.772,4.471,3.678 in the d value, located diffraction peak.
10. the described stilbene glucoside crystal of claim 9, its X-ray powder diffraction spectrogram is that 14.572,12.200,4.772,4.471,3.678,3.622 places have diffraction peak in the d value.
11. the described stilbene glucoside crystal of claim 9 heats up with 10K/ minute speed, its differential scanning calorimetric absorbs the heat deflection peak value and is about 178 ℃.
12. a pharmaceutical composition is characterized in that, contains claim 9,10 or 11 described stilbene glucoside crystal.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100204437A CN101255180B (en) | 2007-02-27 | 2007-02-27 | Diphenyl ethylene glycosides derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100204437A CN101255180B (en) | 2007-02-27 | 2007-02-27 | Diphenyl ethylene glycosides derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010579612 Division CN102060889B (en) | 2007-02-27 | 2007-02-27 | Stilbene glycoside derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101255180A true CN101255180A (en) | 2008-09-03 |
| CN101255180B CN101255180B (en) | 2011-05-04 |
Family
ID=39890334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100204437A Expired - Fee Related CN101255180B (en) | 2007-02-27 | 2007-02-27 | Diphenyl ethylene glycosides derivatives |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101255180B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101787060A (en) * | 2010-03-26 | 2010-07-28 | 卢昶年 | Method for extracting and separating stilbene glucoside from polygonum multiflorum |
| US7824714B2 (en) * | 2008-06-13 | 2010-11-02 | Development Center For Biotechnology | Chinese herb extract for treating dementia and preparation method thereof |
| CN102321129A (en) * | 2011-07-14 | 2012-01-18 | 中国人民解放军第四军医大学 | Stilbene glycoside injection and preparation process thereof |
| CN102659863A (en) * | 2012-05-06 | 2012-09-12 | 中国人民解放军第四军医大学 | Separation and purification process of tetrahydroxy stilbeneglycoside |
| CN102697870A (en) * | 2012-05-30 | 2012-10-03 | 广东医学院 | Anti-osteoporosis effective part of tuber fleeceflower root and extraction method for anti-osteoporosis effective part |
| CN103087123A (en) * | 2013-02-05 | 2013-05-08 | 西安岳达植物科技有限公司 | Method for extracting tetrahydroxystilbene glucoside from Polygonum multiflorum |
| CN103524576A (en) * | 2013-08-12 | 2014-01-22 | 天津中医药大学 | Separation and purification process of 2, 3, 5, 4'-tetrahydroxystilbene-2-O-beta-D-glucoside |
| CN103709213A (en) * | 2013-12-21 | 2014-04-09 | 中国人民解放军第四军医大学 | Process method for extracting and purifying tetrahydroxyl diphenylethylene glycoside from polygonum multiflorum |
| CN104231020A (en) * | 2013-06-14 | 2014-12-24 | 天津大学 | Compound with antioxidant activity and use of compound |
| CN107722079A (en) * | 2017-10-31 | 2018-02-23 | 桂林纽泰生物科技有限公司 | The method that Stibene-glucoside is extracted from the fleece-flower root |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060481C (en) * | 1998-10-14 | 2001-01-10 | 北京中医药大学 | Method for extraction and separation of active component of traditional Chinese medicine fleece flower root |
-
2007
- 2007-02-27 CN CN2007100204437A patent/CN101255180B/en not_active Expired - Fee Related
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7824714B2 (en) * | 2008-06-13 | 2010-11-02 | Development Center For Biotechnology | Chinese herb extract for treating dementia and preparation method thereof |
| CN101787060A (en) * | 2010-03-26 | 2010-07-28 | 卢昶年 | Method for extracting and separating stilbene glucoside from polygonum multiflorum |
| CN102321129B (en) * | 2011-07-14 | 2013-12-18 | 中国人民解放军第四军医大学 | Stilbene glycoside injection and preparation process thereof |
| CN102321129A (en) * | 2011-07-14 | 2012-01-18 | 中国人民解放军第四军医大学 | Stilbene glycoside injection and preparation process thereof |
| CN102659863A (en) * | 2012-05-06 | 2012-09-12 | 中国人民解放军第四军医大学 | Separation and purification process of tetrahydroxy stilbeneglycoside |
| CN102659863B (en) * | 2012-05-06 | 2015-09-23 | 中国人民解放军第四军医大学 | A kind of separation purifying technique of TSG |
| CN102697870A (en) * | 2012-05-30 | 2012-10-03 | 广东医学院 | Anti-osteoporosis effective part of tuber fleeceflower root and extraction method for anti-osteoporosis effective part |
| CN103087123A (en) * | 2013-02-05 | 2013-05-08 | 西安岳达植物科技有限公司 | Method for extracting tetrahydroxystilbene glucoside from Polygonum multiflorum |
| CN104231020A (en) * | 2013-06-14 | 2014-12-24 | 天津大学 | Compound with antioxidant activity and use of compound |
| CN104231020B (en) * | 2013-06-14 | 2016-05-11 | 天津大学 | The compound of antioxidation activity and purposes |
| CN103524576A (en) * | 2013-08-12 | 2014-01-22 | 天津中医药大学 | Separation and purification process of 2, 3, 5, 4'-tetrahydroxystilbene-2-O-beta-D-glucoside |
| CN103709213A (en) * | 2013-12-21 | 2014-04-09 | 中国人民解放军第四军医大学 | Process method for extracting and purifying tetrahydroxyl diphenylethylene glycoside from polygonum multiflorum |
| CN107722079A (en) * | 2017-10-31 | 2018-02-23 | 桂林纽泰生物科技有限公司 | The method that Stibene-glucoside is extracted from the fleece-flower root |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101255180B (en) | 2011-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101255180B (en) | Diphenyl ethylene glycosides derivatives | |
| CN109364119B (en) | Method and application of preparation of total triterpenes with hypoglycemic effect from leaves of C. lucidum | |
| CN101559088B (en) | Production technique of andrographolide and neoandrographolide, dehydroanddrographolide, oxyandrographolide | |
| CN101139320B (en) | Method for separating nuciferine and lotus leaf flavone from lotus leaf | |
| CN111087285B (en) | Method for extracting bibenzyl compounds from dendrobium officinale and application of bibenzyl compounds | |
| CN101003554A (en) | Method for preparing tetrahydroxy diphenyl ethylene glycoside separated from fleece-flower root | |
| CN102060889B (en) | Stilbene glycoside derivative | |
| CN102372754A (en) | Method for preparing specnuezhenide | |
| CN102070683B (en) | Method for simultaneously preparing chemical reference substances of parishin, parishin B and parishin C | |
| CN100422191C (en) | The method for separating and preparing triptolide diol from tripterygium wilfordii | |
| CN101914002A (en) | A kind of extraction method of cyanine A | |
| CN101024604B (en) | Novel dihydrochalcone compound separated and purified from drgon blood and preparation method thereof | |
| CN101759675B (en) | Method for preparing active sesquiterpenes with functions of cancer resistance and bacterium inhibition from ligularia fischeri | |
| CN103880895B (en) | A kind of method of utilizing high speed adverse current chromatogram separation and purification to prepare harpagoside and Wyrmslayer glycosides A | |
| CN105601693A (en) | Preparation of Ginsenoside F1 and Its Antitumor Effect | |
| CN111187323A (en) | Hosta plantaginea flower extract and extraction method and application thereof | |
| CN109912582A (en) | The method of mangiferin is extracted from mango leaf | |
| CN109776515A (en) | The method of mangiferin is extracted from myrica rubra leaf | |
| CN105273015B (en) | A kind of preparation method of high-purity Paeoniflorin and albiflorin | |
| CN102826982A (en) | Monoterpene compounds prepared from Senecio cannabifolius Less, and extraction method and application thereof | |
| CN1935798A (en) | Method for preparing and rographalide | |
| CN108743530B (en) | Preparation method of spina date seed saponin B liposome microemulsion | |
| CN102389456A (en) | Method for extracting isodon japonica var.galaucocalyx total diterpenoids or Glaucocalyxin A | |
| CN102432652A (en) | Method for extracting astilbin from rhizoma smilacis glabrae | |
| CN107074798B (en) | Method for extracting phytoxin from rhodiola rosea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. Effective date: 20110119 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 222006 NO.8, JULONG NORTH ROAD, XINPU DISTRICT, LIANYUN'GANG CITY, JIANGSU PROVINCE TO: 210038 NO.9, HUI'OU ROAD, ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, NANJING CITY, JIANGSU PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110119 Address after: 210038 Jiangsu city of Nanjing Province Economic and Technological Development Zone No. 9 Ou Lu Hui Applicant after: Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Applicant before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Cai Xiaofang Document name: Notice of termination of patent |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110504 Termination date: 20200227 |